MycoMedica Life Sciences, PBC Secures $60 Million in Funding To Fuel Fungi-Based Drug Development for Prevention and Treatment of Psychiatric and Neurological Disorders
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Life Itself Conference – MycoMedica Life Sciences, PBC, a new company focused on developing and delivering fungi-based therapeutic drugs to prevent and treat psychiatric and neurological disorders, today announced it has raised $60 million in funding led by Obvious Ventures, True Ventures and Kittyhawk Ventures. The proceeds from the financing will be used to advance the company’s next stage of operations on the path to FDA approval for an Investigational New Drug Application (IND) – pre-clinical research and initial clinical trials of the Stamets Stack.
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Life Itself Conference – MycoMedica Life Sciences, PBC, a new company focused on developing and delivering fungi-based therapeutic drugs to prevent and treat psychiatric and neurological disorders, today announced it has raised $60 million in funding led by Obvious Ventures, True Ventures and Kittyhawk Ventures. The proceeds from the financing will be used to advance the company’s next stage of operations on the path to FDA approval for an Investigational New Drug Application (IND) – pre-clinical research and initial clinical trials of the Stamets Stack.
TBS Staff
TBS Staff
